Caszyme and Integra Therapeutics sign licensing agreement for novel CRISPR Cas12l nucleases

On November 4, 2024 Caszyme, a pioneer in the development and application of CRISPR gene editing technology, and Integra Therapeutics, a company leading the way in creating advanced therapies based on next-generation gene-writing tools, reported a licensing agreement for the use of Caszyme’s novel Cas12l nucleases to develop safer and more efficient gene and cell therapies (Press release, Integra Therapeutics, NOV 4, 2024, View Source [SID1234654539]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The agreement was unveiled at this year’s BIO Europe, which is the largest partnering event for the biomedical industry in Europe, taking place this week in Stockholm. Over 2,800 companies attended from 60 countries, with more than 5,000 biopharma professionals in attendance.

Under the agreement, Integra Therapeutics will incorporate the genome editor Cas12l into its FiCAT 2.0 (Find and Cut-And-Transfer) gene-writing platform, following successful in vivo and ex vivo studies, which yielded highly positive results in terms of safety and functionality in human cells. Caszyme will receive milestone payments up to 40 million. euros in addition to royalties on sales.

Cas12l is a unique CRISPR nuclease family with an effector size of approximately 850 amino acids that stands out for its small size and versatility. As the demand for efficient and safe gene-editing tools in therapeutic contexts continues to grow, these small nucleases represent a promising solution, combining efficacy with the practical advantages of reduced size. Caszyme-developed Cas12l shows great activity in human cells across multiple targets.

Compared to other nucleases, Caszyme’s Cas12l offers additional delivery possibilities, especially when combined with other effector domains. Moreover, smaller nucleases from non-pathogenic bacteria may be less immunogenic compared to their larger counterparts, further highlighting their therapeutic potential. The nucleases discovered by Caszyme exhibit different characteristics from Cas9 nucleases, which formed the foundation of the find module in FiCAT 1.0, expanding their potential applications in advanced therapies.

"Caszyme’s goal is to enable therapeutic companies to develop novel, efficient and affordable gene editing modalities. This collaboration with Integra Therapeutics is a perfect alignment between two highly innovative European companies, and when successful, will help bring advanced gene editing based therapies to the market." said Dr Monika Paulė, CEO and Co-Founder of Caszyme.

Adding, Dr Giedrius Gasiunas, CSO and Co-Founder of Caszyme, said "the partnership will further Caszyme’s core scientific aims – which are to develop novel, safer and smaller Cas12l nucleases that are more compatible with diverse delivery technologies, such as AAVs, mRNA and LNPs."

Dr Avencia Sánchez-Mejías, CEO and Co-Founder of Integra Therapeutics, added, "This agreement with Caszyme reaffirms our commitment with the excellence in technology development to delivery therapeutic solutions for patients with our gene-writing technology in the preclinical regulatory phase and highlights the success of the transnational project funded by the European Commission, which we launched in 2022 through Eurostars, in support of Europe’s most innovative SMEs."

"The integration of Caszyme nucleases into our FiCAT 2.0 platform strengthens Integra Therapeutics’ mission to develop the highest-quality gene and cell therapy products for the treatment of a wide range of genetic and oncological diseases. FiCAT 2.0 will set itself apart in the market by offering enhanced precision and efficiency," explained Dr Marc Güell, CSO and Co-Founder of Integra Therapeutics.

Neogap Therapeutics partners with NorthX Biologics to advance scalable manufacturing for its novel cancer cell therapy

On November 4, 2024 Neogap Therapeutics, a Swedish clinical-stage biotechnology company, reported that it has entered a strategic collaboration with NorthX Biologics, a leading CDMO, to advance manufacturing strategies for Neogap’s personalised cancer cell therapy (Press release, Neogap Therapeutics, NOV 4, 2024, View Source [SID1234647663]). Supported by ongoing funding from the European Innovation Council (EIC) Accelerator, the partnership aims to optimise and scale production for future clinical trials.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Neogap Therapeutics develops pTTL (personalised Tumour Trained Lymphocytes), a cell therapy designed to treat solid tumours by training the immune system to recognise and attack cancer cells through the patient’s unique neoantigens. Currently, pTTL is under evaluation in a Phase I/II clinical trial focused on assessing its safety and tolerability in patients with advanced colorectal cancer.

The collaboration, carried out within the framework of the EIC Accelerator program, aims to establish a robust, cost-effective production setup that enhances both productivity and scalability.

The project includes a comprehensive analysis of Neogap’s manufacturing protocols, with a focus on scale-out strategies and GMP process industrialisation to support large-scale clinical trials and eventual commercialisation. The goal is to implement streamlined production processes and logistics, increasing resilience and cost-effectiveness as Neogap progresses toward broader clinical applications and greater patient access.

Samuel Svensson, CEO of Neogap Therapeutics, comments: "Partnering with NorthX Biologics is an important step in preparing our therapy for future trials beyond the current Phase 1 study. Establishing a reliable and cost-effective manufacturing process is key to our clinical and commercial goals. We’re excited for our team to work closely with NorthX’s experts, combining our strengths to develop a scalable solution that will allow us to treat a larger patient population as we advance."

Janet Hoogstraate, CEO of NorthX Biologics, comments: "At NorthX Biologics, we are proud to be ‘beyond CDMO’ – a proactive partner that actively contributes to the development of future medicines by collaborating with innovative companies like Neogap Therapeutics. Through our close partnership, we leverage our expertise and Innovation Hub to support at every stage, from initial concept to scalable production of pioneering cell therapies. Together, we are driving groundbreaking innovations forward to improve patients’ lives around the world."

AbCellera Reports Q3 2024 Business Results

On November 4, 2024 AbCellera (Nasdaq: ABCL) reported financial results for the third quarter of 2024 (Press release, AbCellera, NOV 4, 2024, View Source [SID1234647680]). All financial information in this press release is reported in U.S. dollars, unless otherwise indicated.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Through the third quarter we continued to execute on our key priorities of advancing our internal pipeline and building capabilities to support clinical trials activities in 2025 and beyond," said Carl Hansen, Ph.D., founder and CEO of AbCellera. "Notably, we completed the consolidation into our new headquarters in Vancouver, Canada, which marks a significant milestone towards completing our platform and infrastructure investments."

Q3 2024 Business Summary

Expanded existing collaboration with Eli Lilly and Company to discover therapeutic antibodies for programs in immunology, cardiovascular disease, and neuroscience.
Reported the start of two additional partner-initiated programs with downstreams to reach a cumulative total of 95 partner-initiated program starts with downstreams.
Maintained a cumulative total of 14 molecules advanced to the clinic.
Key Business Metrics

Cumulative Metrics

September 30, 2023

September 30, 2024

Change %

Partner-initiated program starts with downstreams

84

95

13%

Molecules in the clinic

10

14

40%

AbCellera started discovery on an additional two partner-initiated programs with downstreams to reach a cumulative total of 95 partner-initiated program starts with downstreams in Q3 2024 (up from 84 on September 30, 2023). AbCellera’s partners have advanced a cumulative total of 14 molecules into the clinic (up from 10 on September 30, 2023).

Discussion of Q3 2024 Financial Results

Revenue – Total revenue was $6.5 million, compared to $6.6 million in Q3 2023. In both periods, the majority of revenues were research fees generated by our partnerships.
Research & Development (R&D) Expenses – R&D expenses were $41.0 million, compared to $37.9 million in Q3 2023, reflecting underlying continued growth in program execution, platform development, and investments in internal programs.
Sales & Marketing (S&M) Expenses – S&M expenses were $3.1 million, compared to $3.5 million in Q3 2023.
General & Administrative (G&A) Expenses – G&A expenses were $19.1 million, compared to $14.4 million in Q3 2023.
Net Loss – Net loss of $51.1 million, or $(0.17) per share on a basic and diluted basis, compared to net loss of $28.6 million, or $(0.10) per share on a basic and diluted basis in Q3 2023.
Liquidity – $670.4 million of total cash, cash equivalents, and marketable securities and with approximately $205 million in available non-dilutive government funding to execute on AbCellera’s strategy, bringing total available liquidity to over $875 million.
Conference Call and Webcast

AbCellera will host a conference call and live webcast to discuss these results today at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time).

The live webcast of the earnings conference call can be accessed on the Events and Presentations section of AbCellera’s Investor Relations website. A replay of the webcast will be available through the same link following the conference call.

Integra LifeSciences Reports Third Quarter 2024 Financial Results

On November 4, 2024 Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, reported financial results for the third quarter ending September 30, 2024 (Press release, Integra LifeSciences, NOV 4, 2024, View Source [SID1234647664]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Third Quarter 2024 Highlights
•Third quarter revenues of $380.8 million decreased 0.4% on a reported basis and 8.6% on an organic basis compared to the prior year. Revenue decreased 10.3% on an organic basis excluding Boston.

•Third quarter GAAP earnings per diluted share of $(0.14), compared to $0.24 in the prior year; adjusted earnings per diluted share of $0.41, compared to $0.76 in the prior year.

•Shipping holds communicated during the second quarter earnings call are releasing in line with expectations.

•Integra Skin production is on pace to meet historical revenue run rates for the fourth quarter.

•Updating full-year 2024 revenue guidance to a range of $1.609 billion to $1.619 billion and adjusted EPS guidance to a range of $2.41 to $2.49 per share.

•The Company announced Mojdeh Poul as Integra’s next president and chief executive officer.

"Our third-quarter results highlight the early progress we are making to identify and remediate the gaps in our quality management system," said Jan De Witte, president and CEO of Integra LifeSciences. "We are progressing with the implementation of our compliance master plan across our manufacturing and supply chain operations, which will position us to meet robust market demand and more consistently and reliably deliver to customers, patients, and shareholders."

Third Quarter 2024 Consolidated Performance

Total reported revenues of $380.8 million decreased 0.4% on a reported basis and 8.6% on an organic basis compared to the prior year. Revenue decreased 10.3% on an organic basis excluding Boston.
The Company reported GAAP gross margin of 52.6%, compared to 57.1% in the third quarter of 2023. Adjusted gross margin was 63.0%, compared to 64.6% in the prior year.
Adjusted EBITDA for the third quarter of 2024 was $61.8 million, or 16.2% of revenue, compared to $88.1 million, or 23.0% of revenue, in the prior year.
The Company reported a GAAP net loss of $(10.7) million, or $(0.14) per diluted share, in the third quarter of 2024, compared to GAAP net income of $19.5 million, or $0.24 per diluted share, in the prior year.

Adjusted net income for the third quarter of 2024 was $31.7 million, or $0.41 per diluted share, compared to $60.5 million, or $0.76 per diluted share, in the prior year.

Third Quarter 2024 Segment Performance
Codman Specialty Surgical (~70% of Revenues)
Total revenues were $270.8 million, representing reported growth of 1.0% and an organic decline of 10.7% compared to the third quarter of 2023.

•Sales in Neurosurgery declined 16.0% on an organic basis
◦The decline was driven primarily by temporary shipping holds in CSF management and Neuro monitoring, which have largely been resolved within the third quarter, as well as supply challenges in Dural access and repair
◦Advanced energy grew mid-single digits driven by CUSA capital and CUSA disposables
•Sales in Instruments grew 8.7% on an organic basis
•ENT reported revenue grew substantially due to the Acclarent acquisition

Tissue Technologies (~30% of Revenues)

Total revenues were $110.1 million, representing a reported decline of 3.6% and organic decline of 3.7% compared to the third quarter of 2023. Tissue Technologies sales were down 9.4% excluding sales of the Company’s products manufactured in Boston. Key drivers for the quarter include:

•Low double-digit decline in Integra Skin due to production challenges
•Low double-digit growth in DuraSorb, MicroMatrix and Cytal
•Sales in private label grew 13.3% on an organic basis

CEO Transition Update

Today, the Company announced Mojdeh Poul as Integra’s next president and chief executive officer. Ms. Poul succeeds Jan De Witte, who previously announced he will retire as president and chief executive officer. Ms. Poul will join Integra on January 6, 2025, at which time she will also be appointed to Integra’s board of directors.

Advancing our Strategy

•Continued strong demand for Integra’s diverse portfolio of leading brands
•Advancing the compliance master plan and investments in supply reliability
◦Neurosurgery shipping holds clearing in line with expectations
◦Integra Skin production is on pace to meet historical revenue run rates for the fourth quarter
•Began installing equipment in Braintree facility
•Continued integration success with the Acclarent ENT products
•Growth in DuraSorb and UBM portfolio remains strong

Balance Sheet, Cash Flow and Capital Allocation
The Company generated cash flow from operations of $22.5 million in the quarter. Total balance sheet debt and net debt at the end of the quarter were $1.81 billion and $1.54 billion, respectively, and the consolidated total leverage ratio was 4.0x.

As of quarter end, the Company had total liquidity of approximately $1.18 billion, including $277 million in cash plus short-term investments and the remainder available under its revolving credit facility.

2024 Outlook
For the fourth quarter 2024, the Company expects reported revenues in the range of $441 million to $451 million, representing reported growth of 11.1% to 13.6% and organic growth of 2.0% to 4.5%. Fourth quarter guidance reflects the integration of Acclarent, stepped up revenue from progress clearing the third-quarter shipping holds, improved production for Integra Skin, partially offset by additional quality holds. The Company expects adjusted EPS in a range of $0.81 to $0.89.

For the full year 2024, the Company is updating its revenue and adjusted EPS ranges of $1.609 billion to $1.619 billion and $2.41 to $2.49, respectively. The revenue range represents reported growth of 4.4% to 5.0% and organic growth of -1.7% to -1.0%.

The Company’s organic sales growth guidance for the fourth quarter and the full year excludes acquisitions and divestitures, as well as the effects of foreign currency.

Conference Call and Presentation Available Online
Integra has scheduled a conference call for 8:30 a.m. ET on Monday November 4, 2024, to discuss third quarter 2024 financial results and forward-looking financial guidance. The conference call will be hosted by Integra’s senior management team and will be open to all listeners. Additional forward-looking information may be discussed in a question-and-answer session following the call. Integra’s management team will reference a presentation during the conference call, which can be found on the Investor section of the website at investor.integralife.com.

A live webcast will be available on the Investors section of the Company’s website at investor.integralife.com. For those planning to participate on the call, register here to receive dial-in details and an individual pin. While not required, it is recommended to join 10 minutes prior to the event’s start. A webcast replay of the conference call will be available on the Investors section of the Company’s website following the call.

Tempus Reports Third Quarter 2024 Results and Agreement to Acquire Ambry Genetics

On November 4, 2024 Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, reported financial results for the quarter that ended September 30, 2024 (Press release, Tempus, NOV 4, 2024, View Source [SID1234647681]). The company also announced that it has entered into an agreement to acquire Ambry Genetics, a leader in genetic testing that aims to improve health by understanding the relationship between genetics and disease.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Revenue increased 33.0% year-over-year to $180.9 million in the third quarter of 2024
Data and services revenue growth accelerated to 64.4% year-over-year
Genomics unit growth accelerated to 23.9% annually with rising average revenue per clinical test
Net Loss of $(75.8 million), which included $22.2 million of stock compensation expense and related employer payroll taxes
Adjusted EBITDA improved $14.4 million year over year to $(21.8 million)
Expect full year 2024 revenue of ~$700 million, which represents ~32% annual growth
For additional information on the quarter, including a letter from our CEO and CFO, please visit our investors relations site at investors.tempus.com.

"The overall business performed well in the quarter, as demonstrated by accelerating volume growth in our genomics business and accelerating revenue growth in our data and services business, specifically within Insights," said Eric Lefkofsky, Founder and CEO of Tempus. "We’re also excited to announce the pending acquisition of Ambry Genetics, which broadens our testing portfolio, expands our disease coverage, and enhances the types of products we can offer to our biotech and pharmaceutical partners. In addition, Ambry is uniquely positioned given that its revenues are currently growing at north of 25% a year and it generates meaningful EBITDA and cash flow."Genomics revenue of $116.4 million in the third quarter of 2024, an increase of $19.6 million or 20.3% over the third quarter of 2023, with 23.9% unit growth.
Data and services revenue of $64.5 million in the third quarter of 2024, an increase of $25.3 million or 64.4% over the third quarter of 2023.
Non-GAAP Genomics gross margin was 49.3% in the third quarter of 2024, compared to 51.9% in the third quarter of 2023, largely related to one-time cash payments in 2023.

Non-GAAP Data and services gross margin was 78.3% in the third quarter of 2024, compared to 60.5% in the third quarter of 2023, led by Insights, or data licensing revenue, which grew 86.6% year over year.
Net Loss of $(75.8 million), which included $22.2 million of stock compensation and related employer payroll taxes compared to net loss of $(552.2 million) in the second quarter of 2024, including $493.1 million of stock compensation and related employer taxes and net loss of $(53.4 million) in the third quarter of 2023.
Adjusted EBITDA $(21.8 million) in the third quarter of 2024, compared to $(31.2 million) in the second quarter of 2024, and $(36.2 million) in the third quarter of 2023.
Ending cash and marketable securities were $466.3 million.
Additional Operating Highlights

Announced a multi-year first of its kind collaboration with BioNTech to leverage Tempus’ TCR dataset in support of BioNTech’s next-generation oncology pipeline.
Announced a 3 year extension with Merck EMD at the culmination of our last 3 year strategic agreement.
Initiated a collaboration with OneOncology to bring more biomarker-driven trials to patients in the community setting at scale.
Initiated the beta launch of our patient-facing app, Olivia, an AI-enabled personal health locker that empowers individuals to holistically organize, store, and manage their own health data through our generative AI healthcare concierge.

Ambry Genetics Acquisition

Tempus reported that it has entered into an agreement to acquire Ambry Genetics, a leader in genetic testing. Under the terms of the agreement, Tempus will pay $375 million in cash and $225 million in shares at closing, of which $100 million will be subject to a lock-up agreement until one year post-transaction close. The deal is expected to be financed in part through a $300 million increase in short and long term debt provided by Ares, Tempus’ current lender. Ambry expects to generate >$300 million in revenue in calendar year 2024 and EBITDA of >$40 million. For more information on Ambry and its impact, see Tempus’ latest investor deck.

Ambry is a leader in hereditary cancer screening and currently serves as Tempus’ main reference lab in this category. The acquisition will provide Tempus with expanded testing capabilities for inherited cancer risk. These services are becoming more and more important for healthcare professionals navigating critical medical decisions with cancer patients and their relatives.

In addition to expanding and enhancing the company’s hereditary screening portfolio, the acquisition of Ambry will complement Tempus’ strategy of using data to advance clinical and scientific innovation. Ambry’s extensive product offerings will also allow Tempus to expand into new disease categories, including pediatrics, rare disease, immunology, women’s reproductive health, and cardiology.

Financial Outlook and Guidance

Tempus continues to expect full year 2024 revenue of approximately $700 million, which represents approximately 32% year-over-year growth and approximately $(105 million) in adjusted EBITDA, an improvement of approximately $50 million over 2023.

Webcast and Conference Call Information

A conference call and webcast will begin today, November 4, 2024 after market close at 4:30 p.m. Eastern Time. Interested parties may access details at:

Conference ID: 7177136
Domestic Dial-in Number: (800) 715-9871
International Dial-in Number: (646) 307-1963
Live Webcast: View Source

The webcast may be accessed on the company’s investor relations website at investors.tempus.com. For those unable to listen to the live webcast, a recording will be made available on the company’s website after the event and will be accessible for one year. Visit the investor relations website to find the company’s latest deck, and commentary on the quarter by Eric Lefkofsky, Founder and CEO and Jim Rogers, CFO, which will be discussed on the conference call and webcast.